Non-Sedating Antihistamine OTC Status Favored By NACDS
This article was originally published in The Tan Sheet
Executive Summary
Rx non-sedating antihistamines should be available over-the-counter, the National Association of Chain Drug Stores states in Aug. 25 comments to the agency.
You may also be interested in...
Claritin patent extension
Schering-Plough's Rx antihistamine's NDA approval was delayed by FDA for two-and-a-half years to gather animal carcinogenicity data, the U.S. General Accounting Office reports Aug. 10. Schering argues the findings strengthen its call for a patent extension due to the extraordinary length of the review - 77.4 months. FDA denies its review took too long, but the company has the support of Senate Judiciary Committee Chairman Orrin Hatch (R-Utah), who has argued any drugs taking more than five years to be approved should be entitled to an extension
Rx Antihistamine Switch Consumer Cost Increases Unlikely, Insurer Tells FDA
Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC